Clinical Trials Logo

Clinical Trial Summary

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.


Clinical Trial Description

Pancreatic cancer is a devastating disease with a dismal prognosis. One of the ways to improve survival might be early detection. Within years, many predisposing diseases or genetic conditions have been identified, thus screening/surveillance have been established worldwide. A registry of subjects at risk of pancreatic cancer will has been built up to investigate the possibility of diagnosis pancreatic cancer, or one if its predisposing lesions. Inclusion criteria will be adopted as "enrollment criteria". According to this, individuals > 18 years old will be enrolled; their familiar history and/or genetic predisposition will be collected, as well as current or previous medical records/medications data. Thereafter, according to specific age-based criteria, those individuals initially enrolled will be will be considered for a "surveillance protocol" ("interventional follow-up criteria") and they will be submitted to Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography according to the pancreatologist's prescription at each participating center. Individuals suffering from the following conditions will be enrolled: familial pancreatic cancer; Peutz-Jeghers syndrome; a known BRCA-2, BRCA-1, PALB2, or p16 mutation with at least one first- or second-degree relative suffering from pancreatic cancer; hereditary pancreatitis; FAMMM syndrome; Lynch syndrome with at least one first- or second-degree relative suffering from pancreatic cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04095195
Study type Observational
Source Associazione Italiana per lo Studio del Pancreas
Contact Salvatore Paiella, MD, PhD
Phone 00390458126009
Email salvatore.paiella@univr.it
Status Recruiting
Phase
Start date August 20, 2019
Completion date September 20, 2045

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00217737 - Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Phase 3
Completed NCT00905710 - Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT04909671 - Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. N/A
Recruiting NCT04379999 - Atorvastatin ± Aspirin in Lynch Syndrome Syndrome Early Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed NCT01845753 - Molecular Screening for Lynch Syndrome in Denmark
Completed NCT01216930 - Molecular Screening for Lynch Syndrome in Southern Denmark N/A
Not yet recruiting NCT05963191 - CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome N/A
Active, not recruiting NCT02912559 - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Phase 3
Recruiting NCT04978350 - Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study N/A
Active, not recruiting NCT03832985 - Pediatric Reporting of Adult-Onset Genomic Results Early Phase 1
Withdrawn NCT04778566 - Evaluating the Cologuard Test for Use in Lynch Syndrome
Completed NCT02570516 - NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome N/A
Completed NCT01823471 - I-Scan For Colon Polyp Detection In HNPCC N/A
Recruiting NCT02813824 - Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Phase 3
Recruiting NCT05078866 - Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients Phase 1/Phase 2
Recruiting NCT03744962 - MSI in Circulatory DNA of Endometrial Cancer
Recruiting NCT04711434 - PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients Phase 3
Completed NCT04131062 - Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants N/A